tiprankstipranks
Trending News
More News >
Spago Nanomedical AB (SE:SPAGO)
:SPAGO

Spago Nanomedical AB (SPAGO) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Spago Nanomedical AB

(Frankfurt:SPAGO)

Rating:38Underperform
Price Target:
Spago Nanomedical AB's overall stock score is driven by significant financial challenges, including persistent losses and negative equity. Despite some upward technical momentum, the stock's negative valuation metrics and lack of profitability weigh heavily on its score. Investors should be cautious due to these financial risks.

Spago Nanomedical AB (SPAGO) vs. iShares MSCI Sweden ETF (EWD)

Spago Nanomedical AB Business Overview & Revenue Model

Company DescriptionSpago Nanomedical AB (SPAGO) is a Swedish biotechnology company focused on developing nanomedical products for the diagnosis and treatment of cancer. The company operates primarily in the healthcare and biotechnology sectors, with its core products centered around proprietary nanomaterial technology designed to enhance the precision and efficacy of cancer therapies and imaging.
How the Company Makes MoneySpago Nanomedical AB generates revenue through the development and commercialization of its nanomedical products, particularly in the oncology space. The company's primary revenue streams include licensing agreements, research and development partnerships, and potential future sales of its nanomedical solutions. Additionally, Spago Nanomedical collaborates with pharmaceutical companies and research institutions, which can provide funding and support for its projects. Revenue is also derived from grants and governmental or institutional funding aimed at advancing innovative cancer treatments and diagnostic tools.

Spago Nanomedical AB Financial Statement Overview

Summary
Spago Nanomedical AB faces substantial financial challenges, characterized by persistent losses, negative equity, and reliance on external financing. While revenue growth is a positive sign, the company must address its operational inefficiencies and improve its cash flow management to achieve financial stability.
Income Statement
30
Negative
Spago Nanomedical AB has shown modest revenue growth in recent years, but it remains a small fraction compared to its substantial operating expenses, resulting in negative gross and net profit margins. The company's EBIT and EBITDA margins are negative, indicating challenges in operational efficiency and profitability.
Balance Sheet
20
Very Negative
The company's balance sheet reveals high liabilities relative to equity, resulting in a negative equity position in the most recent year. The absence of debt is a positive aspect, but the negative stockholders' equity and declining asset base represent significant financial risks.
Cash Flow
25
Negative
Spago Nanomedical AB has consistently negative operating and free cash flows, reflecting cash burn from operations. The company relies on financing activities to support its cash position, indicating potential sustainability issues if external funding becomes constrained.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.91M1.20M1.05M660.00K342.00K
Gross Profit-12.36M-23.28M-15.60M-16.78M-416.00K
EBITDA-33.40M-42.22M-38.73M-38.69M-18.59M
Net Income-32.51M-42.22M-39.31M-39.08M-18.90M
Balance Sheet
Total Assets39.58M52.98M205.95M191.62M162.82M
Cash, Cash Equivalents and Short-Term Investments32.47M45.22M62.10M52.46M28.45M
Total Debt0.000.000.000.000.00
Total Liabilities2.28B11.67M8.80M6.81M3.15M
Stockholders Equity-2.24B41.32M197.16M184.81M159.67M
Cash Flow
Free Cash Flow-34.67M-45.41M-42.02M-40.20M-25.15M
Operating Cash Flow-34.67M-44.91M-38.19M-35.57M-18.77M
Investing Cash Flow-230.00K-506.00K-3.83M-4.63M-6.38M
Financing Cash Flow22.15M28.53M51.66M64.21M41.45M

Spago Nanomedical AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.40
Price Trends
50DMA
0.23
Positive
100DMA
0.22
Positive
200DMA
0.22
Positive
Market Momentum
MACD
0.03
Negative
RSI
57.11
Neutral
STOCH
43.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPAGO, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.23, and above the 200-day MA of 0.22, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 57.11 is Neutral, neither overbought nor oversold. The STOCH value of 43.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SPAGO.

Spago Nanomedical AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
€48.91M
78.14%-94.12%-25.83%
50
Neutral
kr5.39B12.66-80.61%5.12%37.36%27.71%
49
Neutral
€69.38M-66.45%-36.71%72.81%
42
Neutral
kr45.46M-222.24%58.36%
41
Neutral
kr79.18M-46.84%45.38%
38
Underperform
kr104.81M-105.78%58.72%70.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SPAGO
Spago Nanomedical AB
0.31
0.02
5.82%
SE:LARK
CombiGene AB
2.42
-0.41
-14.58%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
25.60
-19.12
-42.75%
SE:MODTX
Modus Therapeutics Holding AB
1.24
-0.01
-0.80%
SE:ONCOZ
OncoZenge AB
6.59
2.92
79.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025